Medtronic plc Logo

Medtronic plc

MDT

(2.2)
Stock Price

81,03 USD

10.95% ROA

8.64% ROE

29.03x PER

Market Cap.

113.038.668.600,00 USD

58.01% DER

3.15% Yield

13% NPM

Medtronic plc Stock Analysis

Medtronic plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Medtronic plc Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 DER

The stock has a low debt to equity ratio (49%), which means it has a small amount of debt compared to the ownership it holds

3 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

4 ROE

ROE in an average range (7.03%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 PBV

The stock's PBV ratio (1.94x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (609) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

11 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Medtronic plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Medtronic plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Medtronic plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Medtronic plc Revenue
Year Revenue Growth
1986 402.800.000
1987 502.000.000 19.76%
1988 653.300.000 23.16%
1989 741.700.000 11.92%
1990 836.600.000 11.34%
1991 1.021.400.000 18.09%
1992 1.176.900.000 13.21%
1993 1.328.200.000 11.39%
1994 1.390.900.000 4.51%
1995 1.742.400.000 20.17%
1996 2.169.100.000 19.67%
1997 2.438.200.000 11.04%
1998 2.604.800.000 6.4%
1999 4.134.100.000 36.99%
2000 5.014.600.000 17.56%
2001 5.551.800.000 9.68%
2002 6.410.800.000 13.4%
2003 7.665.200.000 16.36%
2004 9.087.200.000 15.65%
2005 10.054.600.000 9.62%
2006 11.292.000.000 10.96%
2007 12.299.000.000 8.19%
2008 13.515.000.000 9%
2009 14.599.000.000 7.43%
2010 15.817.000.000 7.7%
2011 15.933.000.000 0.73%
2012 16.184.000.000 1.55%
2013 16.590.000.000 2.45%
2014 17.005.000.000 2.44%
2015 20.261.000.000 16.07%
2016 28.833.000.000 29.73%
2017 29.710.000.000 2.95%
2018 29.953.000.000 0.81%
2019 30.557.000.000 1.98%
2020 28.913.000.000 -5.69%
2021 30.117.000.000 4%
2022 31.686.000.000 4.95%
2023 31.227.000.000 -1.47%
2024 31.936.000.000 2.22%
2024 32.364.000.000 1.32%
2025 31.660.000.000 -2.22%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Medtronic plc Research and Development Expenses
Year Research and Development Expenses Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 156.300.000 100%
1995 191.400.000 18.34%
1996 236.700.000 19.14%
1997 280.200.000 15.52%
1998 297.200.000 5.72%
1999 429.200.000 30.75%
2000 479.700.000 10.53%
2001 577.600.000 16.95%
2002 646.300.000 10.63%
2003 749.400.000 13.76%
2004 851.500.000 11.99%
2005 951.300.000 10.49%
2006 1.112.900.000 14.52%
2007 1.239.000.000 10.18%
2008 1.275.000.000 2.82%
2009 1.355.000.000 5.9%
2010 1.483.000.000 8.63%
2011 1.508.000.000 1.66%
2012 1.490.000.000 -1.21%
2013 1.557.000.000 4.3%
2014 1.477.000.000 -5.42%
2015 1.640.000.000 9.94%
2016 2.224.000.000 26.26%
2017 2.193.000.000 -1.41%
2018 2.253.000.000 2.66%
2019 2.330.000.000 3.3%
2020 2.331.000.000 0.04%
2021 2.493.000.000 6.5%
2022 2.746.000.000 9.21%
2023 2.696.000.000 -1.85%
2024 2.792.000.000 3.44%
2024 2.735.000.000 -2.08%
2025 2.704.000.000 -1.15%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Medtronic plc General and Administrative Expenses
Year General and Administrative Expenses Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%
2024 0 0%
2025 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Medtronic plc EBITDA
Year EBITDA Growth
1986 80.100.000
1987 125.100.000 35.97%
1988 152.400.000 17.91%
1989 145.300.000 -4.89%
1990 199.400.000 27.13%
1991 249.300.000 20.02%
1992 295.100.000 15.52%
1993 335.900.000 12.15%
1994 388.900.000 13.63%
1995 528.000.000 26.34%
1996 729.700.000 27.64%
1997 867.400.000 15.88%
1998 1.186.700.000 26.91%
1999 2.006.300.000 40.85%
2000 1.884.500.000 -6.46%
2001 2.578.900.000 26.93%
2002 3.097.000.000 16.73%
2003 3.366.800.000 8.01%
2004 4.011.300.000 16.07%
2005 4.851.500.000 17.32%
2006 4.878.500.000 0.55%
2007 4.700.000.000 -3.8%
2008 6.035.000.000 22.12%
2009 5.065.000.000 -19.15%
2010 5.037.000.000 -0.56%
2011 6.763.000.000 25.52%
2012 5.258.000.000 -28.62%
2013 5.957.000.000 11.73%
2014 6.673.000.000 10.73%
2015 6.249.000.000 -6.79%
2016 9.211.000.000 32.16%
2017 9.596.000.000 4.01%
2018 9.384.000.000 -2.26%
2019 9.664.000.000 2.9%
2020 8.241.000.000 -17.27%
2021 7.933.000.000 -3.88%
2022 8.932.000.000 11.18%
2023 9.042.000.000 1.22%
2024 9.080.000.000 0.42%
2024 8.379.000.000 -8.37%
2025 8.100.000.000 -3.44%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Medtronic plc Gross Profit
Year Gross Profit Growth
1986 285.300.000
1987 359.200.000 20.57%
1988 472.300.000 23.95%
1989 547.300.000 13.7%
1990 604.200.000 9.42%
1991 736.200.000 17.93%
1992 854.500.000 13.84%
1993 977.700.000 12.6%
1994 1.037.800.000 5.79%
1995 1.308.800.000 20.71%
1996 1.691.200.000 22.61%
1997 1.944.900.000 13.04%
1998 2.072.000.000 6.13%
1999 3.244.400.000 36.14%
2000 3.938.300.000 17.62%
2001 4.438.500.000 11.27%
2002 4.758.100.000 6.72%
2003 5.774.900.000 17.61%
2004 6.834.300.000 15.5%
2005 7.608.200.000 10.17%
2006 8.476.700.000 10.25%
2007 9.131.000.000 7.17%
2008 10.069.000.000 9.32%
2009 11.081.000.000 9.13%
2010 12.005.000.000 7.7%
2011 12.021.000.000 0.13%
2012 12.295.000.000 2.23%
2013 12.464.000.000 1.36%
2014 12.672.000.000 1.64%
2015 13.952.000.000 9.17%
2016 19.691.000.000 29.15%
2017 20.419.000.000 3.57%
2018 20.898.000.000 2.29%
2019 21.402.000.000 2.35%
2020 19.489.000.000 -9.82%
2021 19.634.000.000 0.74%
2022 21.541.000.000 8.85%
2023 20.508.000.000 -5.04%
2024 20.892.000.000 1.84%
2024 19.453.000.000 -7.4%
2025 18.848.000.000 -3.21%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Medtronic plc Net Profit
Year Net Profit Growth
1986 53.400.000
1987 73.800.000 27.64%
1988 86.500.000 14.68%
1989 97.400.000 11.19%
1990 108.700.000 10.4%
1991 133.400.000 18.52%
1992 161.500.000 17.4%
1993 197.200.000 18.1%
1994 232.400.000 15.15%
1995 294.000.000 20.95%
1996 437.800.000 32.85%
1997 530.000.000 17.4%
1998 457.400.000 -15.87%
1999 468.400.000 2.35%
2000 1.098.500.000 57.36%
2001 1.046.000.000 -5.02%
2002 984.000.000 -6.3%
2003 1.599.800.000 38.49%
2004 1.959.300.000 18.35%
2005 1.803.900.000 -8.61%
2006 2.546.700.000 29.17%
2007 2.802.000.000 9.11%
2008 2.231.000.000 -25.59%
2009 2.169.000.000 -2.86%
2010 3.099.000.000 30.01%
2011 3.096.000.000 -0.1%
2012 3.617.000.000 14.4%
2013 3.467.000.000 -4.33%
2014 3.065.000.000 -13.12%
2015 2.675.000.000 -14.58%
2016 3.538.000.000 24.39%
2017 4.028.000.000 12.16%
2018 3.104.000.000 -29.77%
2019 4.631.000.000 32.97%
2020 4.789.000.000 3.3%
2021 3.606.000.000 -32.81%
2022 5.039.000.000 28.44%
2023 3.758.000.000 -34.09%
2024 3.636.000.000 -3.36%
2024 3.676.000.000 1.09%
2025 4.168.000.000 11.8%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Medtronic plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1986 0
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 1 0%
1998 1 0%
1999 0 0%
2000 1 0%
2001 1 0%
2002 1 0%
2003 1 100%
2004 2 0%
2005 1 0%
2006 2 50%
2007 2 0%
2008 2 -100%
2009 2 0%
2010 3 50%
2011 3 0%
2012 3 33.33%
2013 3 0%
2014 3 0%
2015 2 -50%
2016 3 0%
2017 3 0%
2018 2 0%
2019 3 33.33%
2020 4 0%
2021 3 -50%
2022 4 33.33%
2023 3 -50%
2024 3 0%
2024 3 0%
2025 3 33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Medtronic plc Free Cashflow
Year Free Cashflow Growth
1990 51.500.000
1991 60.800.000 15.3%
1992 74.200.000 18.06%
1993 214.400.000 65.39%
1994 296.100.000 27.59%
1995 290.300.000 -2%
1996 336.700.000 13.78%
1997 273.400.000 -23.15%
1998 441.900.000 38.13%
1999 -788.500.000 156.04%
2000 699.900.000 212.66%
2001 1.391.800.000 49.71%
2002 1.203.800.000 -15.62%
2003 1.697.800.000 29.1%
2004 2.421.200.000 29.88%
2005 2.367.400.000 -2.27%
2006 963.200.000 -145.78%
2007 2.285.000.000 57.85%
2008 2.883.000.000 20.74%
2009 3.215.000.000 10.33%
2010 3.496.000.000 8.04%
2011 3.193.000.000 -9.49%
2012 3.853.000.000 17.13%
2013 4.426.000.000 12.95%
2014 4.563.000.000 3%
2015 4.331.000.000 -5.36%
2016 4.172.000.000 -3.81%
2017 5.626.000.000 25.84%
2018 3.616.000.000 -55.59%
2019 5.873.000.000 38.43%
2020 6.021.000.000 2.46%
2021 4.885.000.000 -23.25%
2022 5.978.000.000 18.28%
2023 4.580.000.000 -30.52%
2024 200.000.000 -2190%
2024 5.200.000.000 96.15%
2025 466.000.000 -1015.88%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Medtronic plc Operating Cashflow
Year Operating Cashflow Growth
1990 106.800.000
1991 126.600.000 15.64%
1992 151.400.000 16.38%
1993 291.500.000 48.06%
1994 356.900.000 18.32%
1995 387.200.000 7.83%
1996 500.500.000 22.64%
1997 463.600.000 -7.96%
1998 590.100.000 21.44%
1999 455.300.000 -29.61%
2000 1.042.000.000 56.31%
2001 1.831.500.000 43.11%
2002 1.590.200.000 -15.17%
2003 2.078.200.000 23.48%
2004 2.845.800.000 26.97%
2005 2.819.400.000 -0.94%
2006 2.207.400.000 -27.72%
2007 2.979.000.000 25.9%
2008 3.489.000.000 14.62%
2009 3.878.000.000 10.03%
2010 4.131.000.000 6.12%
2011 3.741.000.000 -10.43%
2012 4.381.000.000 14.61%
2013 4.883.000.000 10.28%
2014 4.959.000.000 1.53%
2015 4.902.000.000 -1.16%
2016 5.218.000.000 6.06%
2017 6.880.000.000 24.16%
2018 4.684.000.000 -46.88%
2019 7.007.000.000 33.15%
2020 7.234.000.000 3.14%
2021 6.240.000.000 -15.93%
2022 7.346.000.000 15.06%
2023 6.039.000.000 -21.64%
2024 661.000.000 -813.62%
2024 6.787.000.000 90.26%
2025 986.000.000 -588.34%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Medtronic plc Capital Expenditure
Year Capital Expenditure Growth
1990 55.300.000
1991 65.800.000 15.96%
1992 77.200.000 14.77%
1993 77.100.000 -0.13%
1994 60.800.000 -26.81%
1995 96.900.000 37.25%
1996 163.800.000 40.84%
1997 190.200.000 13.88%
1998 148.200.000 -28.34%
1999 1.243.800.000 88.08%
2000 342.100.000 -263.58%
2001 439.700.000 22.2%
2002 386.400.000 -13.79%
2003 380.400.000 -1.58%
2004 424.600.000 10.41%
2005 452.000.000 6.06%
2006 1.244.200.000 63.67%
2007 694.000.000 -79.28%
2008 606.000.000 -14.52%
2009 663.000.000 8.6%
2010 635.000.000 -4.41%
2011 548.000.000 -15.88%
2012 528.000.000 -3.79%
2013 457.000.000 -15.54%
2014 396.000.000 -15.4%
2015 571.000.000 30.65%
2016 1.046.000.000 45.41%
2017 1.254.000.000 16.59%
2018 1.068.000.000 -17.42%
2019 1.134.000.000 5.82%
2020 1.213.000.000 6.51%
2021 1.355.000.000 10.48%
2022 1.368.000.000 0.95%
2023 1.459.000.000 6.24%
2024 461.000.000 -216.49%
2024 1.587.000.000 70.95%
2025 520.000.000 -205.19%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Medtronic plc Equity
Year Equity Growth
1986 348.700.000
1987 387.000.000 9.9%
1988 395.900.000 2.25%
1989 473.600.000 16.41%
1990 541.000.000 12.46%
1991 683.200.000 20.81%
1992 796.500.000 14.22%
1993 841.500.000 5.35%
1994 1.053.500.000 20.12%
1995 1.335.000.000 21.09%
1996 1.789.300.000 25.39%
1997 1.746.200.000 -2.47%
1998 2.044.200.000 14.58%
1999 3.654.600.000 44.07%
2000 4.491.500.000 18.63%
2001 5.509.500.000 18.48%
2002 6.431.100.000 14.33%
2003 7.906.400.000 18.66%
2004 9.077.000.000 12.9%
2005 10.449.500.000 13.13%
2006 9.382.500.000 -11.37%
2007 10.977.000.000 14.53%
2008 11.536.000.000 4.85%
2009 12.851.000.000 10.23%
2010 14.629.000.000 12.15%
2011 15.968.000.000 8.39%
2012 17.113.000.000 6.69%
2013 18.671.000.000 8.34%
2014 19.443.000.000 3.97%
2015 53.230.000.000 63.47%
2016 51.828.000.000 -2.71%
2017 50.416.000.000 -2.8%
2018 50.822.000.000 0.8%
2019 50.212.000.000 -1.21%
2020 50.872.000.000 1.3%
2021 51.602.000.000 1.41%
2022 52.722.000.000 2.12%
2023 51.665.000.000 -2.05%
2024 50.420.000.000 -2.47%
2024 51.647.000.000 2.38%
2025 48.160.000.000 -7.24%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Medtronic plc Assets
Year Assets Growth
1986 527.400.000
1987 559.700.000 5.77%
1988 640.800.000 12.66%
1989 759.600.000 15.64%
1990 856.500.000 11.31%
1991 1.024.100.000 16.37%
1992 1.163.500.000 11.98%
1993 1.286.500.000 9.56%
1994 1.623.300.000 20.75%
1995 1.946.700.000 16.61%
1996 2.503.300.000 22.23%
1997 2.409.200.000 -3.91%
1998 2.774.700.000 13.17%
1999 4.870.300.000 43.03%
2000 5.669.400.000 14.09%
2001 7.038.900.000 19.46%
2002 10.904.500.000 35.45%
2003 12.320.800.000 11.5%
2004 14.110.800.000 12.69%
2005 16.617.400.000 15.08%
2006 19.664.800.000 15.5%
2007 19.512.000.000 -0.78%
2008 22.198.000.000 12.1%
2009 23.661.000.000 6.18%
2010 28.090.000.000 15.77%
2011 30.424.000.000 7.67%
2012 33.083.000.000 8.04%
2013 34.794.000.000 4.92%
2014 37.943.000.000 8.3%
2015 106.685.000.000 64.43%
2016 99.547.000.000 -7.17%
2017 99.816.000.000 0.27%
2018 91.393.000.000 -9.22%
2019 89.694.000.000 -1.89%
2020 90.689.000.000 1.1%
2021 93.083.000.000 2.57%
2022 90.981.000.000 -2.31%
2023 90.948.000.000 -0.04%
2024 89.981.000.000 -1.07%
2024 90.087.000.000 0.12%
2025 89.749.000.000 -0.38%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Medtronic plc Liabilities
Year Liabilities Growth
1986 178.700.000
1987 172.700.000 -3.47%
1988 244.900.000 29.48%
1989 286.000.000 14.37%
1990 315.500.000 9.35%
1991 340.900.000 7.45%
1992 367.000.000 7.11%
1993 445.000.000 17.53%
1994 569.800.000 21.9%
1995 611.700.000 6.85%
1996 714.000.000 14.33%
1997 663.000.000 -7.69%
1998 730.500.000 9.24%
1999 1.215.700.000 39.91%
2000 1.177.900.000 -3.21%
2001 1.529.400.000 22.98%
2002 4.473.400.000 65.81%
2003 4.414.400.000 -1.34%
2004 5.033.800.000 12.3%
2005 6.167.900.000 18.39%
2006 10.282.300.000 40.01%
2007 8.535.000.000 -20.47%
2008 10.662.000.000 19.95%
2009 10.810.000.000 1.37%
2010 13.461.000.000 19.69%
2011 14.456.000.000 6.88%
2012 15.970.000.000 9.48%
2013 16.123.000.000 0.95%
2014 18.500.000.000 12.85%
2015 53.455.000.000 65.39%
2016 47.719.000.000 -12.02%
2017 49.400.000.000 3.4%
2018 40.571.000.000 -21.76%
2019 39.482.000.000 -2.76%
2020 39.817.000.000 0.84%
2021 41.481.000.000 4.01%
2022 38.259.000.000 -8.42%
2023 39.283.000.000 2.61%
2024 39.561.000.000 0.7%
2024 38.440.000.000 -2.92%
2025 41.589.000.000 7.57%

Medtronic plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
25.19
Net Income per Share
3.04
Price to Earning Ratio
29.03x
Price To Sales Ratio
3.47x
POCF Ratio
16.53
PFCF Ratio
21.97
Price to Book Ratio
2.38
EV to Sales
4.29
EV Over EBITDA
17.54
EV to Operating CashFlow
20.24
EV to FreeCashFlow
27.13
Earnings Yield
0.03
FreeCashFlow Yield
0.05
Market Cap
113,04 Bil.
Enterprise Value
139,59 Bil.
Graham Number
50.33
Graham NetNet
-20.51

Income Statement Metrics

Net Income per Share
3.04
Income Quality
1.76
ROE
0.08
Return On Assets
0.05
Return On Capital Employed
0.08
Net Income per EBT
0.83
EBT Per Ebit
0.88
Ebit per Revenue
0.18
Effective Tax Rate
0.16

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.63
Operating Profit Margin
0.18
Pretax Profit Margin
0.16
Net Profit Margin
0.13

Dividends

Dividend Yield
0.03
Dividend Yield %
3.15
Payout Ratio
0.93
Dividend Per Share
2.78

Operating Metrics

Operating Cashflow per Share
5.33
Free CashFlow per Share
3.98
Capex to Operating CashFlow
0.25
Capex to Revenue
0.05
Capex to Depreciation
0.66
Return on Invested Capital
0.06
Return on Tangible Assets
0.11
Days Sales Outstanding
67.35
Days Payables Outstanding
68.89
Days of Inventory on Hand
162.8
Receivables Turnover
5.42
Payables Turnover
5.3
Inventory Turnover
2.24
Capex per Share
1.36

Balance Sheet

Cash per Share
6,06
Book Value per Share
37,24
Tangible Book Value per Share
-4.44
Shareholders Equity per Share
37.07
Interest Debt per Share
22.08
Debt to Equity
0.58
Debt to Assets
0.31
Net Debt to EBITDA
3.34
Current Ratio
2.13
Tangible Asset Value
-5,74 Bil.
Net Current Asset Value
-19,64 Bil.
Invested Capital
71843000000
Working Capital
11,66 Bil.
Intangibles to Total Assets
0.6
Average Receivables
6,07 Bil.
Average Payables
2,35 Bil.
Average Inventory
5315500000
Debt to Market Cap
0.25

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Medtronic plc Dividends
Year Dividends Growth
1982 1
1983 1 0%
1984 1 0%
1985 1 0%
1986 1 0%
1987 1 0%
1988 1 0%
1989 1 100%
1990 1 0%
1991 1 0%
1992 1 0%
1993 1 0%
1994 1 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 100%
2013 1 0%
2014 1 0%
2015 1 0%
2016 2 0%
2017 2 0%
2018 1 0%
2019 2 50%
2020 2 0%
2021 2 0%
2022 3 0%
2023 3 0%
2024 2 0%

Medtronic plc Profile

About Medtronic plc

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

CEO
Mr. Geoffrey Straub Martha
Employee
95.000
Address
20 On Hatch
Dublin, 2

Medtronic plc Executives & BODs

Medtronic plc Executives & BODs
# Name Age
1 Dr. Laura Mauri M.D., M.Sc.
Senior Vice President and Chief Scientific & Medical Officer
70
2 Mr. Gregory L. Smith
Executive Vice President of Global Operations & Supply Chain
70
3 Ms. Jennifer M. Kirk
Senior Vice President, Global Controller & Chief Accounting Officer
70
4 Gary Corona
Senior Vice President of Global Financial Planning and Analysis & Interim Chief Financial Officer
70
5 Mr. Geoffrey Straub Martha
Chairman of the Board & Chief Executive Officer
70
6 Dr. Kenneth E. Washington Ph.D.
Senior Vice President and Chief Technology & Innovation Officer
70
7 Mr. Mark Ploof
Senior Vice President of Global Operations and Business Services
70
8 Mr. Ryan Weispfenning
Vice President & Head of Investor Relations
70
9 Mr. Brett A. Wall
Executive Vice President & President of Neuroscience Portfolio
70
10 Mr. Sean M. Salmon
Executive Vice President & President of Cardiovascular Portfolio
70

Medtronic plc Competitors